Journal: World neurosurgery

Article Title: Brain Metastases: Surgical treatment and overall survival.

PMID/MRN: 27667577

Publication Date: 2016-Sep-22

Abstract:

Brain metastases occur between 10 and 40% of patients with cancer and are more common than primary brain tumors (30-40%) and their incidence is growing because of the improvements in control of systemic disease, the prolonged survival and the better radiological detection. Modern treatment of brain metastases dramatically changed their expected prognosis that traditionally has been considered very poor referring such patients only to palliation because their terminal stage, and new prognostic indexes have been proposed to evaluate them. The aim of our study was to determine the long-term incidence of surgery on overall survival (OS) in patients with brain metastases from dissimilar primary tumors and to identify the prognostic variables associated with a prolonged survival. Surgical resection should be considered the primary option for brain metastases and together with stereotactic radiosurgery must be evaluated for single brain metastases and also for multiple lesions up to 3. We retrospectively reviewed a consecutive series of patients operated between January 2010 and October 2014 for cerebral metastases from lung, kidney, breast and gastrointestinal cancers plus melanoma. Among the variables, we include age, sex, histology, location of lesions and specific treatments that these patients have undergone including chemotherapy, radiotherapy and surgery, individually or in combination of them. At admission, all the patients underwent an oncological evaluation considering their general health conditions according to specific scales (ECOCG) and their prognostic classification according with the Radiation Therapy Oncology Group (RTOG) one. None worsened after surgery and, at discharge, 19 (26.76%) patients demonstrated an unchanged postoperative neurological examination while 52 patients (73.23%) showed an improvement (chi 2 34.84, p-value < 0.0001). The expected overall survival, considering all tumor subtypes, was 372.24 months but the patients in our series obtained an overall survival of 787 months, more than twice than expected; specifically, the average expected survival of each patient was of 5.24 months while the obtained was 11.08 (p-value 0.000008). We believe that surgery is a safe and effective procedure for cerebral metastases and should not be considered an aggressive treatment in such disease because in our series 55% of the patients had a survival longer than 6 months and a significant improvement in term of obtained vs expected survival. Copyright © 2016 Elsevier Inc. All rights reserved.